First-in-human trial shows Cyclarity’s UDP-003 can safely bind and excrete 7-ketocholesterol, potentially reversing atherosclerosis. Cyclarity Therapeutics’ UDP-003 achieves first safe removal...
UDP-003, a cyclodextrin-based drug, safely reduces 7-ketocholesterol in Phase 1, potentially reversing atherosclerosis instead of just slowing it. A novel drug that removes toxic cholesterol byproduct...
